Sildenafil Found Beneficial in Pediatric PAH

نویسنده

  • Robyn J. Barst
چکیده

BALTIMORE – Cystic fibrosis–related diabetes differs from type 1 and 2 diabetes and requires different management. “Screening early and knowing which patients are at risk is really important,” Amanda Leonard said at a meeting on pediatric nutrition sponsored by Johns Hopkins University. Pulmonary function begins to decline several years before diagnosis of cystic fibrosis– related diabetes (CFRD), so identifying and treating patients with CFRD can have a big impact on life expectancy, said Ms. Leonard, a senior pediatric clinical dietician at the Johns Hopkins Cystic Fibrosis Center. Although CFRD is very different from type 1 and type 2 diabetes, “it does share some components,” she said. She summarized the highlights of the clinical care guidelines for CFRD issued by the American Diabetes Association and the Cystic Fibrosis Foundation (Diabetes Care 2010;33:2697-708). CFRD is associated with Sildenafil Found Beneficial in Pediatric PAH

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

تعیین شاخص های فارماکوکینتیکی شربت سیلدنافیل در هیپرتانسیون ریوی کودکان

Background and purpose: Pulmonary arterial hypertension (PAH) is a fatal disease affecting patients in all ages that could result in acute and chronic heart failure with high mortality rate. Oral sildenafil is approved to treat PAH in adults and recently in children. There are limited studies on the pharmacokinetics parameters of sildenafil, therefore, this study was designed to determine the p...

متن کامل

Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension

Sildenafil is a phosphodiesterase type-5 inhibitor approved for treatment of pulmonary arterial hypertension (PAH) in adults. Data from pediatric trials demonstrate a similar acute safety profile to the adult population but have raised concerns regarding the safety of long-term use in children. Interpretation of these trials remains controversial with major regulatory agencies differing in thei...

متن کامل

Sildenafil for the treatment of pulmonary hypertension in children.

Pulmonary hypertension, including pulmonary arterial hypertension (PAH), is a serious disease in children, but few clinical studies have been conducted to evaluate treatment regimens in this population. Currently, treatment of children with PAH is mostly based on clinical studies conducted in adults and a few dedicated pediatric studies. Sildenafil, a phosphodiesterase type 5 inhibitor, has an ...

متن کامل

Reported Sildenafil Side Effects in Pediatric Pulmonary Hypertension Patients

BACKGROUND Sildenafil, a phosphodiestase type 5 inhibitor, was approved in 2005 for the treatment of pulmonary arterial hypertension (PAH) in adults and is commonly used off-label for pediatric patients. Little is known, however, about sildenafil's side effects in this population. METHODS Single institution, longitudinal survey-based study performed in an outpatient pediatric cardiology clini...

متن کامل

Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension.

OBJECTIVE Mutations in the bone morphogenetic protein type II receptor (BMPR-II) are responsible for the majority of cases of heritable pulmonary arterial hypertension (PAH), and BMPR-II deficiency contributes to idiopathic and experimental forms of PAH. Sildenafil, a potent type-5 nucleotide-dependent phosphodiesterase inhibitor, is an established treatment for PAH, but whether sildenafil affe...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2011